While food, shelter, and clothing are the primal essentials for life, hope-as embodied by modern medicine-has now become part of that human expectation.
David Deere
Advertisement
David Deere is the chief commercialization officer for PaizaBio, a US-based contract manufacturing organization and consulting group with in-country aseptic fill-and-finish operations in Hangzhou, China. Deere is a veteran global pharmaceutical executive whose career path includes Valeant Pharmaceuticals International, F. Hoffman-La Roche and Genentech.
Articles by David Deere
Quality, innovation, and new approval pathways open drug development options for the Chinese market, including injectable contract manufacturing.
Advertisement
Latest Updated Articles
Regulatory Reform in China Creates OpportunitiesPublished: August 1st 2016 | Updated:
- Biosimilars and Healthcare Policy: What China Can Learn from the EU and US
Published: September 28th 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Dosage Form Innovations: A CPHI Frankfurt Conversation with Lonza’s Frank Romanski, Part One
2
PharmTech Weekly News Roundup — Week of October 27, 2025
3
Drug Digest: Strategic Alliances and Technology Integration in the Evolving Biopharma Landscape
4
Clearing Hurdles in Sustainability, AI, and CDMO Partnerships
5
